PriceTargets.com logo

Cardiol Therapeutics - CRDL Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: C$0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$1.33 As of 12/4/2025 05:00 PM ET
+0 (0.00%)

This chart shows the closing price for CRDL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cardiol Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRDL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRDL

Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cardiol Therapeutics in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$1.33.

This chart shows the closing price for CRDL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Cardiol Therapeutics. This rating has held steady since April 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/22/2024HC WainwrightReiterated RatingBuy
11/8/2022Raymond James FinancialLower TargetMarket PerformC$3.00 ➝ C$1.00
9/1/2022Raymond James FinancialLower TargetMarket PerformC$4.00 ➝ C$3.00
4/18/2022Canaccord Genuity GroupReiterated RatingBuyC$7.00
3/17/2022Raymond James FinancialDowngradeOutperform ➝ HoldC$5.00 ➝ C$4.00
2/4/2022Raymond James FinancialReiterated RatingOutperformC$5.00
12/17/2021Cantor FitzgeraldInitiated CoverageBuyC$8.00
11/12/2021Raymond James FinancialSet TargetOutperformC$5.00
8/25/2021Raymond James FinancialBoost TargetOutperformC$4.50 ➝ C$5.00
5/19/2021ATB CapitalLower TargetC$6.00 ➝ C$5.50
5/17/2021Raymond James FinancialBoost TargetOutperformC$4.25 ➝ C$4.50
4/29/2021Raymond James FinancialUpgradeMarket Perform ➝ OutperformC$4.25
4/14/2021Raymond James FinancialReiterated RatingMarket PerformC$4.25
4/5/2021ATB CapitalLower TargetSpeculative BuyC$6.30 ➝ C$6.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 1 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 1 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Cardiol Therapeutics logo
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.
Read More

Today's Range

Now: C$1.33
Low: C$1.31
High: C$1.37

50 Day Range

MA: C$1.49
Low: C$1.29
High: C$1.72

52 Week Range

Now: C$1.33
Low: C$1.09
High: C$2.17

Volume

59,968 shs

Average Volume

109,150 shs

Market Capitalization

C$133.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.305872

Frequently Asked Questions

What sell-side analysts currently cover shares of Cardiol Therapeutics?

The following sell-side analysts have issued reports on Cardiol Therapeutics in the last year:
View the latest analyst ratings for CRDL.

What is the current price target for Cardiol Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Cardiol Therapeutics in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Cardiol Therapeutics in the next year.
View the latest price targets for CRDL.

What is the current consensus analyst rating for Cardiol Therapeutics?

Cardiol Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CRDL.

What other companies compete with Cardiol Therapeutics?

Other companies that are similar to Cardiol Therapeutics include Dalradian Resources, International Tower Hill Mines, Fennec Pharmaceuticals, VBI Vaccines and Chemtrade Electrochem Inc,. Learn More about companies similar to Cardiol Therapeutics.

How do I contact Cardiol Therapeutics' investor relations team?

Cardiol Therapeutics' physical mailing address is 2265 Upper Middle Road East, Suite 602, Oakville, ON L6H 0G5, Canada, . The company's listed phone number is 289 910 0850. The official website for Cardiol Therapeutics is www.cardiolrx.com. Learn More about contacing Cardiol Therapeutics investor relations.